investordatabase.org

Vesalius Biocapital IV Partners SàRL

vesaliusbiocapital-4.com Direct investor

Vesalius Biocapital IV Partners SàRL is a European life sciences venture capital firm investing in Biopharma and HealthTech companies. It is currently fundraising for its fourth fund, targeting €150M+ and 10-12 deals.

Vesalius Biocapital IV Partners SàRL is a venture capital firm headquartered in Contern, Luxembourg. It invests directly in companies, from seed to growth, in drug development, medical devices & diagnostics, eHealth / mHealth and biopharma. Its stated cheque size is €10-15M per deal. €150M+ under management, as it reports.

“We are investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe.”

— Vesalius Biocapital IV Partners SàRL, own website
Layer
Direct investor
Type
Venture capital
Stage
Seed – Growth
Headquarters
Contern, Luxembourg
Invests in
Europe
Sectors
drug development, medical devices & diagnostics, eHealth / mHealth, Biopharma, HealthTech
Cheque size
€10-15M per deal
Assets under management
€150M+

Team, as Vesalius Biocapital IV Partners SàRL publishes it

  • Guy Geldhof Managing Partner
  • Jean-Christophe Renondin Managing Partner
  • Stephane Verdood Managing Partner
  • Olivier Houben Partner
  • Fabienne Roussel Partner
  • Qasim Al-Zawawi Principal/ CFO
  • David Cristina Principal
  • Hayley French Venture Partner
  • Virginie Michielsen Conducting Officer
  • Pauki Tran Controller
  • Judith Murazishya Management Assistant

Names and roles exactly as listed on vesaliusbiocapital-4.com. Nothing else about these people is recorded.

Where this comes from

Every fact above was read from a page Vesalius Biocapital IV Partners SàRL publishes itself. Nothing is taken from third-party databases. Investment activity (deals, co-investors) is not yet recorded.

Is this record wrong or stale? Report a mistake — it reaches us directly, no email address to look up.

Record 9267 · added 2026-09-29 · link last verified 2026-09-29 · confidence high

Similar investors

Listed under